The history of Sildenafil presents a intricate picture for shareholders. While the initial release generated significant gains, the expiration of its intellectual property protection opened the avenue to cheaper versions, dramatically eroding sales. This poses a unique risk for pharmaceutical companies banking on similar blockbuster medications, su

The story of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in sales , its exclusivity period created a deluge of generic competition , significantly eroding its dominance. While specific pharmaceutical companies may try to capitalize on related treatments , the pr